Key result
Lidocaine use in acute myocardial infarction should be limited to patients with very frequent and complex ventricular arrhythmias due to serious side effects and narrow preventive efficacy.
Why the study?
Should lidocaine be used prophylactically or selectively for the prevention of malignant ventricular arrhythmias in the early phase of acute myocardial infarction?
Should lidocaine be used prophylactically or selectively for the prevention of malignant ventricular arrhythmias in the early phase of acute myocardial infarction?
Lidocaine use in acute myocardial infarction should be restricted to selective treatment of frequent and complex ventricular arrhythmias rather than routine prophylactic administration due to side effects and limited efficacy.
Answers are grounded in this paper and cite their sources.
Supports restricting lidocaine to frequent complex arrhythmias in AMI; leaves open need for contemporary RCTs.
In acute myocardial infarction, lidocaine is considered the drug of choice for the treatment of malignant ventricular arrhythmias. While initially a so-called "selective" treatment strategy prevailed, in which lidocaine was administered only after the onset of certain "warning arrhythmias," the prophylactic use of lidocaine in acute myocardial infarction has been gaining wider usage in intravenous and intramuscular application in recent years. Both therapeutic applications have been found to be problematic of late, which has led to increasingly restrictive use of lidocaine. While in selective treatment forms, the definition and prompt recognition of the so-called warning arrhythmias created especially acute problems, the prophylactic therapeutic use is problematic due to the occurrence of sometimes serious side effects, which is to be expected as the size of the collective being treated increases. Both treatment forms also appear limited by the narrow preventive efficacy of lidocaine against malignant ventricular arrhythmias, especially against ventricular fibrillation. The current therapeutic recommendation for lidocaine in acute myocardial infarction should be limited to patients presenting with very frequent and complex ventricular arrhythmias, especially when these are elicited by an R-on-T phenomenon. Side effects and other therapeutic problems encountered when the therapeutic modality is switched or adjusted can be greatly reduced by careful dosing and selection of the optimal combination substances.
No takes yet. Share an insight, caveat, or question.
Zehender et al. (1990) conducted a review in Acute myocardial infarction. Lidocaine was evaluated. Lidocaine use in acute myocardial infarction should be limited to patients with very frequent and complex ventricular arrhythmias due to serious side effects and narrow preventive efficacy.
Synapse has enriched 10 related papers. Consider them for comparative context: